|
|
Blood, 1 February 2008, Vol. 111, No. 3, pp. 1302-1305.
Prepublished online as a Blood First Edition Paper on November 9, 2007; DOI 10.1182/blood-2007-06-094318.
 Previous Article | Next Article 
Submitted June 11, 2007
Accepted November 2, 2007
Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels
Patrick Au, Laurence M Daheron, Dan G Duda, Kenneth S Cohen, James A Tyrrell, Ryan M Lanning, Dai Fukumura, David T Scadden, and Rakesh K. Jain*
Edwin L. Steele Laboratory, Dept of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Center for Regenerative Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Harvard-MIT Division of Health Sciences & Technology, Massachusetts Institute of Technology, Cambridge, MA, United States
Harvard Stem Cell Institute, Cambridge, MA, United States
* Corresponding author; email: jain{at}steele.mgh.harvard.edu.
Tissue engineering requires formation of a de novo stable vascular network. Because of their ability to proliferate, differentiate into endothelial cells and form new vessels, blood-derived endothelial progenitor cells (EPCs) are attractive source of cells for use in engineering blood vessels. However, the durability and function of EPC-derived vessels implanted in vivo are unclear. To this end, we directly compared formation and functions of tissue-engineered blood vessels generated by peripheral blood- and umbilical cord blood-derived EPCs in a model of in vivo vasculogenesis. We found that adult peripheral blood EPCs form blood vessels that are unstable and regress within three weeks. In contrast, umbilical cord blood EPCs form normal-functioning blood vessels that last for more than 4 months. These vessels exhibit normal blood flow, perm-selectivity to macromolecules and induction of leukocyte-endothelial interactions in response to cytokine activation similar to normal vessels. Thus, umbilical cord blood EPCs hold great therapeutic potential and their use should be pursued for vascular engineering.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. M. Melero-Martin, M. E. De Obaldia, S.-Y. Kang, Z. A. Khan, L. Yuan, P. Oettgen, and J. Bischoff
Engineering Robust and Functional Vascular Networks In Vivo With Human Adult and Cord Blood-Derived Progenitor Cells
Circ. Res.,
July 18, 2008;
103(2):
194 - 202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Au, J. Tam, D. Fukumura, and R. K. Jain
Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature
Blood,
May 1, 2008;
111(9):
4551 - 4558.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
